What is the safety and efficacy of ACE inhibitors and ARBs after CABG in previously na ve low-to moderate-risk patients?
The safety and efficacy of ACE inhibitors and ARBs after CABG in previously na ve low-to moderate-risk patients (ie, subjects without diabetes mellitus or renal insufficiency and with or Hillis et al 2011 ACCF/AHA CABG Guideline e681 without asymptomatic moderate LV systolic dysfunction) are uncertain; furthermore, ACE inhibitors and ARBs must be used with caution in these subjects.